CSNK1D and myotonic dystrophy type 1: Furthermore, 35 or 65 μM of erythromycin increased inclusion of CSNK1D exon 9 and MPRIP exon 9 compared to placebo treated DM1 hiNeurons (p = 0.0258, p = 0.0060, respectively for CSNK1D and p = 0.0023, p = 0.0024, respectively for MPRIP).